dapagliflozin
astrazeneca
[]
#esccongress2022 the #deliver study did it : 18% reduction of the primary endpoint in hfmref and hfpef patients 
Head of cardiology, ICCU & cathlab, FESC @chru_tours @T2i_research #Medicalpedagogy @FacmedTours @UnivTours @SFCardio ???????? @uoftalumni @fedecardio